BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology, an LG Chem company (“AVEO”), today announced The Oncologist has published a post-hoc analysis of long-term progression free survival, overall survival and safety data from the Phase 3 TIVO-3 trial evaluating FOTIVDA® (tivozanib) in patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC).

波士顿，2024年2月6日（环球通讯社）--LG化学公司（“AVEO”）AVEO Oncology今天宣布，肿瘤学家发表了一项对复发或难治性（R/R）晚期肾细胞癌（RCC）患者的长期无进展生存期，总生存期和安全性数据进行事后分析的第3阶段TIVO-3试验评估了FOTIVDA®（tivozanib）。

In the publication, FOTIVDA demonstrated a consistent safety profile and a long-term survival benefit in patients who were alive and progression-free at 12 months, suggesting a durable clinical benefit and safety across age groups regardless of prior treatment. “The post-hoc analysis from TIVO-3 provides additional evidence supporting the clinical utility of tivozanib in the third- or fourth-line refractory setting in patients with advanced renal cell carcinoma,” said lead author Kathryn E.

在该出版物中，FOTIVDA在12个月时存活且无进展的患者中表现出一致的安全性和长期生存益处，表明无论之前的治疗如何，各年龄组都具有持久的临床益处和安全性。“TIVO-3的事后分析提供了额外的证据，支持tivozanib在晚期肾细胞癌患者的三线或四线难治性环境中的临床应用，”主要作者KathrynE。

Beckermann, MD, PhD, Assistant Professor of Medicine in the Division of Hematology Oncology at Vanderbilt-Ingram Cancer Center. “The results suggest there is a clinically meaningful population of patients who can experience a long-term survival benefit from tivozanib over sorafenib.” TIVO-3 compared the efficacy and safety of the vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) FOTIVDA and sorafenib (Nexavar®) in patients with R/R advanced RCC whose disease progressed with two or three prior systemic therapies.

贝克曼，医学博士，博士，范德比尔特英格拉姆癌症中心血液肿瘤科医学助理教授。“结果表明，有临床意义的患者群体可以从替沃扎尼而不是索拉非尼中获得长期生存益处。“TIVO-3比较了血管内皮生长因子受体（VEGFR）酪氨酸激酶抑制剂（TKIs）FOTIVDA和索拉非尼（Nexavar®）对R/R晚期RCC患者的疗效和安全性，这些患者的疾病通过两种或三种先前的全身治疗进展。

The trial included a predefined subgroup of patients (26%) who were previously treated with both an immuno-oncology (IO) therapy and a VEGFR TKI. The post hoc analysis showed investigator-assessed landmark long-term progression-free survival (PFS) rates were higher with FOTIVDA compared to sorafenib (3 years: 12.3% vs.

该试验包括先前接受过免疫肿瘤学（IO）治疗和VEGFR TKI治疗的预定义亚组患者（26%）。事后分析显示，研究者评估的标志性长期无进展生存率（PFS）高于索拉非尼（3年：12.3%vs。

2.4%; 4 years: 7.6% vs. 0%). After 22.8 months mean follo.

2.4%；4年：7.6%比0%）。22.8个月后平均随访。